- Lobbying
- boehringer AND ingelheim AND pharmaceuticals
Lobbying Arrangements Results for 'Boehringer Ingelheim Pharmaceuticals'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details H.R. 7047, Lowering Costs by Improving Biosimilar Uptake Act |
Boehringer Ingelheim Pharmaceuticals, Inc.
Pharmaceutical company |
KING & SPALDING LLP | |||
Details Phamaceutical issues, especially with respect to the House Energy and Commerce Committee. Our work is specifically related to the Connecticut delegation. Issues related to tariff suspension |
Boehringer Ingelheim Pharmeceutical
|
The Moffett Group, LLC | |||
Details Monitoring legislation pertaining to Healthcare issues |
Boehringer Ingelheim
|
Venable LLP | |||
Details Issues related to coverage and reimbursement for those who are covered by the Medicare and Medicaid programs; Issues related to expansion of the Medicaid drug rebate program; Issues affecting provi... |
Boehringer-Ingelheim Pharmaceuticals, Inc
|
RICCHETTI INCORPORATED | |||
Details Physician Payment Sunshine Act S 2029 Patent Settlements H.R. 14328 .316 Affordable Healthcare Choices Act |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
RUBICON ADVISORS, LLC | |||
Details Medicare payments |
Boehringer Ingelhem Pharamaceuticals Inc
|
Hogan Lovells US LLP | |||
Details Issues related to regulatory and legislative developments regarding biosimilars and prescription digital therapeutics. |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
alb solutions | |||
Details Issues related to the Biologics Price Competition and Innovation Act of 2009. Issues related to FDA user fee legislation, including S. 4348, the Food and Drug Administration Safety and Landmark Adv... |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
Sims Strategies, LLC | |||
Details Implementation issues affecting biopharmaceutical manufacturers related to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliati... |
Boehringer-Ingelheim Pharmaceuticals, Inc.
|
Jennifer Bell + Partners | |||
Details S. 999 & H.R. 477- Stop Stroke Act; S. 2029 & H.R. 5605, Physician Payments Sunshine Act of 2007; H.R. 3610- Food and Drug Importation Safety Act; H.R. 5839- Safeguarding America's Pharmaceuticals ... |
Boehringer Ingelheim Pharmacuticals, Inc.
|
Brown Rudnick LLP | |||
Details S. 515, H.R. 1260, Patent Reform Act of 2009, S. 525/1252, H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009, S. 729, H.R. 1427, Promoting Innovation and Access to Live-Savings Me... |
Boehringer-Ingelheim Pharmaceuticals, Inc.
Pharmaceutical company |
PATTON BOGGS LLP | |||
Details Issues related to diabetes and cardiovascular disease |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
JEFFREY J. KIMBELL AND ASSOCIATES | |||
Details Medicare Part D, evidence-based medicine, transparency, False Claims Act, patent reform, drug pedigree. H.R. 1, The American Recovery and Reinvestment Act |
Boehringer & Ingelheim Pharmaceuticals
|
ALSTON & BIRD, LLP | |||
Details ADUFA and general agriculture issues |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
FGS Global (US) LLC (FKA FGH Holdings LLC) | |||
Details DOJ policy regarding off label communications. |
Medical Information Working Group
|
SIDLEY AUSTIN LLP | |||
Details Issues related to supply chain policy, prescription digital therapeutics. Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars. Issu... |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
Thorn Run Partners | |||
Details Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. CHIP. Rebates for dual eligible and low-income subsidy population in Medicare Part D. Non-I... |
Boehringer Ingelheim Pharmaceuticals, Inc.
|
AMERICAN CONTINENTAL GROUP | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property ... |
BOEHRINGER INGELHEIM USA CORPORATION
|
BOEHRINGER INGELHEIM USA CORPORATION, formerly reported as Boehringer Ingelheim Pharmaceuticals, Inc | |||
Details Pharmaceutical distribution and supply chain security. |
Pharmaceutical Distribution Security Alliance (PDSA)
|
Leavitt Partners, LLC | |||
Details HR.1585, National Defense Authorization Act for Fiscal Year 2008 HR.5839, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs S.2731, Tom Lantos and Henry J. Hyde Unite... |
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
|
BOCKORNY GROUP, INC. |